Introduction
Individuals with bipolar disorder (BD) are known to have worse physical health and reduced life expectancy compared to the general population (Crump et al., 2013) . Excess cardiovascular mortality in BD is partly attributed to metabolic syndrome (Fagiolini et al., 2005) and diabetes mellitus (DM) (De Hert et al., 2009) , which both occur with higher than expected prevalences in this population (37.3-41.1% and 26% respectively) (Alosaimi et al., 2017; Fagiolini et al., 2005; Vancampfort et al., 2013) . Patients with BD have a 1.7-3.2 times higher risk of DM compared with age-and gender-matched controls (Charles et al., 2016; Vancampfort et al., 2015) . Patients with comorbid BD and DM type 2 or insulin resistance have greater morbidity, lower treatment response, greater chronicity, and disability, as well as more prominent brain structure alterations (Hajek et al., 2016) . Multiple factors mediating metabolic alterations in BD range from socioeconomic and behavioral problems (insufficient social support, sedentary lifestyle, insufficient self-care, passive coping skills, treatment non-compliance), comorbidities (eating disorders, smoking, and alcohol misuse), to neurobiological factors and the adverse effect of psychotropic medications (Bauer et al., 2014; Gomes et al., 2013; Iwen et al., 2013; Janney et al., 2014;  J o u r n a l P r e -p r o o f Nestsiarovich et al. Li et al., 2013; McElroy and Keck, 2014) .
Psychopharmacotherapy safety is a priority concern for BD patients (Nestsiarovich et al., 2017) , and the potential of psychotropic drugs to induce glucose metabolism abnormalities is well established (Al-Zoairy et al., 2013; Correll et al., 2015) . Drug-induced insulin resistance may result from the indirect effect of medications via induced weight gain/obesity, and/or from the direct action on production, transport and action of insulin, including reduced sensitivity and toxic destruction of pancreatic β-cells, antagonized central and peripheral acetylcholine M3 receptors (Weston-Green et al., 2013) , and increased TNF-α levels produced by adipocytes (Filaković et al., 2012) . Psychotropic-naïve mentally ill individuals were reported to have an increased prevalence of hyperglycemia, but a decreased prevalence of obesity when compared to the general population -evidence supporting the existence of two separate risk pathways for these metabolic conditions following exposure to a medication (Sun et al., 2018) .
The findings from multiple studies on psychotropic drug-induced DM or metabolic syndrome show notable reproducibility, providing evidence of the diabetogenic potential of the majority of psychiatric drug classes, in particular, of antipsychotics (Correll et al., 2015; Gianfrancesco et al., 2003 Gianfrancesco et al., , 2002 , and antidepressants (Correll et al., 2015; Salvi et al., 2017) . Nevertheless, discrepancies still remain on the comparative safety of BD drug classes and individual medications (Wake et al., 2016) , and very limited data are available on the safety profile of psychotropic polypharmacy, which is used in 36-85% of patients with BD in the US (Fornaro et al., 2016) . Methodological inconsistencies among published studies include different outcomes of interest (metabolic syndrome, DM alone), categories of patients (youth, elderly, adults, veterans, pregnant females), diagnoses (psychiatric disorder, mood disorder, psychosis, Alzheimer's disease, BD), and patient selection criteria (with or without previous/current glucose metabolism abnormalities).
No guidelines are currently available to inform DM-prevention strategies of choosing one BD drug over another, monotherapy versus polypharmacy, or one multi-drug regimen versus the other. This study aimed to compare all pharmacotherapy regimens commonly used by US adults with BD for the risk of subsequently observed DM.
Patients and methods
A retrospective cohort study was performed using the IBM MarketScan® administrative claims data (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) on 932,815 commercially insured US inpatients and outpatients with BD (Quint, 2015) .
The database contained records of provider visits, diagnoses, procedures, outpatient prescription fills, laboratory test orders (but not results), and patient age, sex, and state of residence. The data handling was similar to our previous study on drug-dependent risk of kidney disorders in BD (Nestsiarovich et al., 2019) . The relevant PostgreSQL queries and Python data transformations are available online at this repository: https://gitlab.com/PCORIUNMPUBLIC/diabetes_public. The study protocol was approved by the University of New Mexico Human Research Review Committee (Institutional Review Board number 16-243).
The sample was restricted to patients who received antidepressants, antipsychotics, lithium, or mood stabilizing anticonvulsants at least once following the BD-related index visit (defined below). Inclusion criteria were: age 18-64 years at index exposure (defined below) and two or more ICD 9-CM/ICD 10-CM diagnostic codes for BD (296.[0-1]*, 296.[4-8]*, F30*, F31*) during 2003-2015. Exclusion criteria were: diagnosis of schizophrenia, schizoaffective disorder, chronic delusional disorders, intellectual disabilities, autism spectrum disorders, mental illness of organic origin, or Parkinson's disease at any time during the observation period, or receiving anti-dementia drugs at any time point ( Supplementary Table 1 ). Patients were excluded who received insulin or were diagnosed with any glucose metabolism-related disorder prior to index exposure; the codes are available in the aforementioned repository. All exclusion criteria are listed in Supplementary Table 1 . To avoid multiple coding of one event, we constructed a "meta-visit" by merging consecutive outpatient/inpatient/emergency room (ER) visits, with no gap larger than one day.
A patient was included in the analysis based on the following first observed sequence of events ( Figure 1 ): 1) A minimum of 12 months of observation (used to compute pre-treatment covariates); 2) "Index visit" -meta-visit with at least one BD diagnostic code; 3) "Index exposure" -first day of exposure to a regimen (including "No drug") observable on the last day of the index visit; 4) "Timevarying drug exposure period" -series of time intervals in which distinct regimens (including "No drug") were prescribed; and 5) Outcomes of interest: i) the first meta-visit with a newly observed DM type 2 or "unspecified"; ii) right censoring defined as any hospitalization/ER meta-visit without DM code, or the end of patient observation. A subset of the excluded conditions, which are unlikely to be caused by psychotropic medications, were used as additional criteria for censoring when a patient had the relevant code after pharmacotherapy start (Supplementary Table 2 ).
The observation period was ended for patients upon DM-unrelated hospitalization/ER metavisit, because data on pharmacotherapy were not available during these types of visits, making it challenging to quantify psychotropic treatment time intervals. Also, other hospitalizations might affect the risk of DM via iatrogenic factors.
The start and stop time was recorded for each treatment exposure period. A Cox regression model for DM was built comparing the risk of 102 pharmacotherapies versus the "No drug" regimen, as well as against each other. "No drug" was chosen as a comparator based on input from patients with BD who participated in several focus groups and were engaged in shaping this research (Nestsiarovich et al., 2017) . This allowed us to address their questions regarding the safety and effectiveness of avoiding pharmacotherapy and to have a common denominator representing the "baseline" DM risk for each individual.
To ensure sufficient power to detect a significant difference each drug regimen was required to have ≥1000 treatment intervals and to have ≥5 defined cases of DM immediately following exposure (Vittinghoff and McCulloch, 2007) .
The following 11 drug classes were included in the analysis: lithium, first-generation antipsychotics (FGAs), second-generation antipsychotics (SGAs), "third generation antipsychotics" (TGAs, partial agonists of dopamine receptors, aripiprazole and brexpiprazole), mood-stabilizing anticonvulsants (MSAs), monoamine oxidase inhibitor antidepressants (MAOIs), noradrenergic and specific serotonergic antidepressants (NASSA, represented by mirtazapine only), norepinephrinedopamine reuptake inhibitors (NDRIs, represented by bupropion only), serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), and tri-and tetracyclic antidepressants ( Supplementary Table 3 ).
MSAs, SGAs, and TGAs were also studied as individual drugs. SGAs common enough for individual analysis were: risperidone, olanzapine, quetiapine, ziprasidone, asenapine, paliperidone, and lurasidone. Individual MSAs studied were: valproate, carbamazepine, oxcarbazepine, and lamotrigine. Of the two TGAs, only aripiprazole was common enough to be studied individually.
Combinations of two, three, or four of the 11 drug classes with the requisite ≥1000 treatment intervals and ≥5 DM events were included in the regression model, and drug regimens without those requisites were grouped under the categories "polypharmacy 2", "polypharmacy 3", and "polypharmacy 4" (for uncommon combinations of 2, 3 and ≥4 classes, respectively). Enough instances of within-class polypharmacy were present among MSAs and SGAs to include "multi-MSA", and "multi-SGA" variables.
Monotherapies without the requisite 1000 exposure intervals (clozapine, brexpiprazole, and iloperidone) were combined into the category "uncommon monotherapy".
Treatment was represented as one or more exposure intervals within a time-varying covariate Cox regression model, with all categories mutually exclusive and collectively exhaustive, and using the "No drug" category as the reference. The rules to distinguish between polypharmacy and drug regimen switch, as well as the analysis software used, are described in our previous study of a similar design (Nestsiarovich et al., 2019) .
Among the covariates included in the analyses were patient age, sex, BD episode index visit characteristics (severity, mood polarity, psychotic features, if documented), comorbid physical and mental conditions, medication prescriptions (except for drugs of interest) filled and mental health procedures performed one year before (but not including) the index exposure, hospital/ER admissions one year prior to index exposure, type of visits composing the index meta-visit (inpatient/ER/outpatient).
Using the covariance structure of the regression model, we also performed comparisons of two-drug combinations versus monotherapies, three-drug combinations versus two-drug combinations, and fourdrug combinations versus three-drug treatments.
Given more than a hundred treatment comparators chosen and the time-varying nature of covariates in our design, propensity score matching was not feasible for bias correction. Instead, we used a resolution IV fractional factorial design of experiments to select an appropriate subset of the 85 pre-treatment covariates to control for bias (main effects were aliased with 3-way interactions, and 2way interactions were aliased with 2-way interactions). We ran 512 different variations of the Cox models on DM outcome to determine which variables had the largest impact on the drug HR coefficients. The main effect was the presence or absence of the corresponding non-treatment covariate in the model. We generated a distance metric (L2-norm) for regression coefficients of all regimens in the models with (N=256) or without (N=256) the covariate. Covariates with larger changes in the distance metric when they were included vs. excluded from the models were selected for inclusion. Supplementary Table 4 lists all the 85 covariates.
Results
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The sample characteristics at different stages of the study are depicted in Figure 2 . A total of 565,253 adults met the inclusion criteria and had the pre-specified sequence of events. Of them, 95.9% were censored and 4.1% (22,951) had a newly observed DM. Among those censored, 48.5% were admitted to a hospital/ER for DM-unrelated conditions. Supplementary Table 5 shows a summary of the outcomes by treatment time intervals.
During the observation period after the index visit, the annual incidence of new-onset DM was 3.09% (3.39% for regimens other than "No drug"), appearing within a mean of 342.7 days (median 136) after the index visit, based on 741,573 years of observation under the drug regimens studied. For comparison, the annual incidence of "No drug" was 2.85%.
The 659 observed treatment regimens were collapsed to 19 monotherapies and 83 drug combinations that fit the selection criteria. The "No drug" regimen was observed in 27.3% of the time intervals, monotherapy in 40.37%, and polypharmacy in 32.4% of the treatment intervals. The Cox regression model (Table 1) showed that 39 out of 102 studied drugs/drug combinations were associated with a significantly higher risk of DM compared to the "No drug" regimen (p<0.05, no multiple testing correction). The highest risk of DM was observed for multi-drug combinations containing antidepressants, MSAs, antipsychotics, as well as for uncommon drug monotherapy. Nine out of the 102 studied pharmacotherapies were associated with significantly lower risk of DM, compared to the "No drug" regimen, and included monotherapies (lamotrigine, lithium, oxcarbazepine, bupropion), SSRI mono-class therapy, and several SSRI-and bupropion-containing combinations. The lowest risk of DM was observed for lamotrigine monotherapy, followed by monotherapies with oxcarbazepine, bupropion, and lithium; combinations "NDRI+SSRI", "NDRI+MSA", "SSRI+lithium"; SSRI mono-class therapy; and the "SSRI+MSA" regimen.
A comparative analysis of treatment regimens of different levels of complexity (from "No drug" to monotherapies, to four-drug combinations) is displayed in Figure 3 drug polypharmacy therapies were directly compared to constituent {k-1}-drug therapies, most of the significant HRs showed higher DM risk for k-drug regimens. In other words, the more BD drugs were added downwards along the vertical "axis", the higher were the observed HR values.
Out of the 81 studied multi-drug combinations (Table 1) , 31 were associated with significantly higher risk of DM compared to "No drug", and four with significantly lower risk of DM. Out of 21 studied monotherapies, seven had significantly higher risk of DM, and five had significantly lower risk of DM. All four studied FGA-containing regimens had significantly higher risk of newly observed DM compared to the "No drug" regimen (HR range 1.59-2.09). Twenty out of 38 SGA-containing treatments, as well as 10 out of 22 TGA-containing treatments, were also associated with significantly higher risk of DM, compared to "No drug" (HR range 1.14-2.37, and 1.28-2.18, respectively). The risk of DM in aripiprazole monotherapy did not differ significantly from "No drug". Out of 40 studied MSA-containing treatments, 12 had significantly higher risk of DM, and four had significantly lower risk of DM compared to "No drug". Two of the 4 MSA monotherapies were associated with lower DM risk (lamotrigine, oxcarbazepine). Out of 24 studied lithium-containing treatments, five were associated with higher risk of DM, and two with lower risk of DM than "No drug", including lithium monotherapy (HR=0.80, 95%CI=0.74-0.86, p=2.39x10 -9 ). Out of 71 studied antidepressant-containing drug regimens, 21 had higher risk of DM and six had lower risk of DM, the latter consisting of NDRI and SSRI combinations.
Among the six studied antidepressant mono-class therapies, the highest HR estimates were observed for tri-and tetracyclic antidepressants, followed by SNRIs, MAOIs, NASSA, and SSRIs. Only NDRI mono-class therapy was associated with significantly lower DM risk (HR=0.80, 95%CI=0.72-0.88, p<0.05).
Out of 85 pre-treatment covariates, 30 were identified as impacting drug HR estimates and were thus included in the Cox regression model. Nine of these were associated with significantly higher risk of DM and nineteen with lower risk of DM (Table 1) . 
Discussion
Our findings show that the annual incidence of DM is markedly higher in patients on the investigated regimens than the reported numbers for diabetes in the general US population (3.39% versus 0.32-0.88%) (Geiss et al., 2014) , which is comparable with previously reported data on psychotropic drug-dependent DM (Chang et al., 2015) . Given that a 2.85% incidence is observed following pharmacotherapy-free time intervals (on "No drug" regimen), the observed increase in DM risk might be more attributable to BD pathophysiology or patient lifestyle, rather than treatments. The average patient age of 37 years could also explain the relatively high DM rates in the studied population, as the prodromal phase of this disease could have already occurred.
The majority of the BD treatment regimens studied were associated with a 1.07-2.37 fold increased risk of DM onset compared to "No drug" (p<0.05), including combinations most commonly used in routine psychiatric care: "MSA+SGA", "SGA+SSRI", "SGA+SNRI", "MSA+TGA", "TGA+SSRI", and "lithium+TGA". These observations should raise awareness among practitioners about possible alterations in glucose metabolism in patients with BD, not only in those treated with SGAs, but also in patients treated with FGAs, and multi-drug combinations containing MSAs and antidepressants.
Asenapine monotherapy had one of the highest HRs of all the studied regimens. It is considered a "middle-risk" weight gain-inducing antipsychotic together with quetiapine and risperidone (Musil et al. 2015) . Concerns regarding its influence on prolactin levels have been raised (Citrome, 2009), but there is yet no clear evidence on its diabetogenic properties. Interestingly, the risk of SSRIs was greatly dependent on whether they were used alone (as a monoclass) or in combination with another drug/drug class. The fact that antidepressants were used in patients who were already diagnosed with The finding that drug HR estimates were generally significantly higher for complex combinations rather than for more simple regimens or monotherapies (Figure 3) , adds to the evidence suggesting a detrimental impact of psychotropic polypharmacy on patients' physical health (Correll et al., 2015) , and the potential consequences of additive damage when using multiple BD drugs simultaneously.
Unlike a previous comparative safety study of BD treatments, focusing on several monotherapies (Hayes et al., 2016) , our study revealed a 3-fold difference in DM risk among multiple psychotropic regimens, and found that several of the regimens were associated with a significantly lower DM risk compared to "No drug". Three of the low-risk regimens were mood stabilizer monotherapies, namely, lithium, lamotrigine, and oxcarbazepine. Lithium-dependent risk of weight gain is described in multiple studies (McKnight et al., 2012) , and is believed to result from increased appetite, hypothyroidism, and nephrogenic diabetes insipidus with increased thirst. Data on the effect of lithium on glucose metabolism are conflicting. Several follow-up studies on psychiatric patients failed to show any significant association of lithium use with glucose and insulin plasma concentrations (Aprahamian et al., 2014; McIntyre et al., 2011) . Another recent international follow-up study on lithium-treated patients with BD reported an increase of blood glucose levels by 0.79% per year, with time to the firstobserved significant increase to be 6-10 years (Tondo et al., 2017) . Lamotrigine is considered to be a well-tolerated drug, free of significant negative effects on weight (Grootens et al., 2018) , except for singular cases noted in FDA adverse event reports by physicians (Ursu et al., 2018) . It was shown to be effective in binge eating patients by facilitating weight loss, reducing the blood levels of insulin, triglycerides and fasting glucose (Guerdjikova et al., 2009) . In a patient with a comorbid binge-eating disorder and BD, it was associated with reduced hemoglobin A1c levels (Yamamoto et al., 2013) .
Oxcarbazepine was shown to be neutral for body weight, serum levels of glucose, insulin, insulin growth factor-binding proteins-1 and 3, and ghrelin in children with epilepsy (Cansu et al., 2011; Rättyä et al., 1999) , and did not affect the fasting insulin serum levels in adult men with epilepsy (Pylvänen et al., J o u r n a l P r e -p r o o f 13 Nestsiarovich et al. 2003) . With regard to bupropion, the data support its weight-neutral properties (Serretti and Mandelli, 2010) and beneficial role in the management of obesity, glucose, and lipid metabolism disturbances (Anderson et al., 2002; Hollander et al., 2013) . Moreover, it appears to be contraindicated in patients with significant weight loss (Ursu et al., 2018) . SSRIs are generally considered to have a low risk of metabolic syndrome, although the data are conflicting (Fjukstad et al., 2016; Roopan and Larsen, 2017) .
The association of lithium, lamotrigine, oxcarbazepine, and bupropion with a lower risk of DM might be explained by their relatively high therapeutic effectiveness, alleviating patients' apathy and sedentary lifestyle, and/or preventing the cortisol-releasing effect of distress/negative emotions. The lower risk might also be explained by a safer metabolic profile, with less alteration of glucose biochemical pathways.
Our findings support previously published data on increased DM risk in patients on antipsychotics (Vancampfort et al., 2016) , which is consistent with FDA warnings ( Supplementary Table   6 ). However, we did not find robust evidence supporting the results from other studies showing a higher DM risk for tricyclic antidepressants (Siafis and Papazisis, 2018) , the antidepressant group as a whole (Salvi et al., 2017) , as well as olanzapine and mirtazapine (Gianfrancesco et al., 2003 (Gianfrancesco et al., , 2002 ).
It appears to be an open question to what extent the observed DM risks are mediated by weight
gain. Being a covariate in our regression model, weight gain/obesity showed a significant association with an increased risk of DM. However, we recognize that poor coding of weight abnormalities in administrative claims data makes correction for this factor only partial. Although lithium, valproate, lamotrigine, olanzapine, quetiapine, and mirtazapine are known for their weight-gain properties (Grootens et al., 2018; Ursu et al., 2018) , in our study, they were not significantly associated with an increased risk for DM compared to "No drug". These discrepancies could suggest the existence of different pathophysiologic pathways for drug-induced DM, both related and unrelated to weight gain.
There might be other reasons why our study failed to reproduce previously reported findings on the high diabetogenic potential of olanzapine, such as indication bias. Due to rising pharmacovigilance on this drug's adverse metabolic effects (Ketter and Haupt, 2006) , clinicians could prescribe it to healthier and younger patients with no DM risk factors. In general, much of the current knowledge on olanzapine-induced DM is based on relatively outdated research: a Pubmed search on "olanzapine" and "diabetes" shows that most clinical studies exploring this association were performed more than 15 years ago, and modern studies tend to focus on animal models. It should also be acknowledged that many of the reported olanzapine-induced DM cases can be secondary to overweight/obesity, for which many studies fail to control Thus, the weight-independent DM-inducing potential of olanzapine (Balbão et al., 2014) remains underinvestigated. In addition, the large body of evidence on olanzapine metabolic adversity comes from the studies on schizophrenia patients (Feng and Melkersson, 2012) , who may be more vulnerable to drug-induced weight gain than those with BD (Moteshafi et al., 2012) . Finally, many studies put in doubt the high diabetogenic potential of olanzapine (Guha et al., 2005; Yasui-Furukori et al., 2009; Smith et al., 2009) , and those with positive findings focus on glucose and insulin measures rather than on verified DM diagnosis (Sato et al., 2010) .
Advantages of this study, compared to others, is that we explored the largest number of BD drug regimens used in the US to date, and the cohort was restricted to patients with BD. We also: (i) included only diabetes-naive patients; (ii) controlled for multiple baseline patient-related covariates, including obesity; and (iii) implemented a statistical approach to account for time-varying exposures.
Finally, the study provided evidence on DM risk for psychotropic polypharmacy versus monotherapy, a topical but under-investigated question for both psychiatric care providers and patients with BD.
The study limitation inherent in all observational studies of administrative claims data is the non-randomized assignment of patients to treatment groups. No patient data were available prior to their insurance enrollment date, as well as prior to 2003. Thus, the baseline risk for DM development and detection could differ among the studied individuals. Although illness severity codes were included J o u r n a l P r e -p r o o f in the modeling process, unmeasured indication or other biases could distort drug risk estimates for DM (e.g. family history of diabetes, ethnicity, and patient lifestyle). No correction was made for the number of drugs of interest used prior to treatment exposure, thus, treatment "responders" could be compared to "non-responders", and the higher risks for a given polypharmacy regimen may be confounded with the risks of earlier drug exposures. Finally, no correction was made for medication dosage, route of administration, or release mechanism.
Conclusions
1. The risk of a DM on pharmacotherapy versus "No drug" varied 3-fold among different psychotropic regimens.
2. Several pharmacotherapies were associated with significantly lower DM risk compared to "No drug": lithium, lamotrigine, oxcarbazepine, and bupropion monotherapies, SSRI mono-class therapy, and bupropion-and SSRI-containing drug combinations.
3.
A relatively high risk of DM in psychotropic polypharmacy and antipsychotic-containing regimens requires more attention from researchers and clinicians.
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